Clinical Trial Details

Overview

Research Study Summary

TAKEDA EXAMINE trial patients for who have Type II diabetes & ACS coronary artery disease, post angiogram or heart attack. This is a phase 3b study. Currently open for enrollment.

Purpose

The purpose of this study is to evaluate the cardiovascular outcomes of alogliptin compared with placebo, in addition to standard of care, in patients with type II diabetes mellitus and acute coronary syndrome.

Patient Inclusion Criteria:
In order to participate in this study you need to have a hgA1c level between 6.5-11.0% , and a history of ACS (acute coronary syndrome) that required hospitalization with in 15-90 days prior to randomization.

Patient Exclusion Criteria:

  • Signs of type I diabetes mellitus
  • currently receiving a glucagon- like peptide 1 for glycemic control.
  • Hemodynamically unstable cardiovascular disorder including heart failure
  • Received or is receiving dialysis
  • Patient has human immunodeficiency virus
  • Alcohol or substance abuse

To Learn more

CW ID: 181277
Date Last Changed: July 18, 2013

Clinical Trial Snapshot

Phase
4
Gender
Both Male and Female
Age
N/A
Overall Status
Recruiting
Facility Type
N/A

Contact

Nasra Hashmi, Clinical Research Specialist
Coastal Multi-Specialty Research
2621 S. Bristol St. Suite 108A
Santa Ana, CA 92704
Phone: 714-754-1684

View Map

Volunteer for this Trial

If you would like to learn more about participating in this research study, please email the trial contact using the form below. We value your privacy and your information will only be used by the research center to contact you regarding this study.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.